Figure 2.

CBD reduces viability independently of CB₁, CB₂, TRPV1, or GPR55. (A) Prostate cancer cells (DU145, PC-3) were treated with SR141716 (CB₁ antagonist) for 1 h before the addition of an IC₅₀ dose of CBD for 72 h. Cell viability was determined by using the MTT assay. (B) Cells were treated with SR144528 (CB₂ antagonist) for 1 h before the addition of an IC₅₀ dose of CBD for 72 h. Cell viability was determined using the MTT assay. (C) Cells were treated with capsazepine (CPZ) (TRPV1 antagonist) for 1 h before the addition of an IC₅₀ dose of CBD for 72 h. Cell viability was determined using the MTT assay. (D) Cells were treated with lysophosphatidylinositol (LPI) (GPR55 agonist) for 1 h before the addition of an IC₅₀ dose of CBD for 72 h. Cell viability was determined using the MTT assay. Data are represented as mean ± SD calculated from at least three independent experiments. *p < 0.05 compared to cells treated with CBD alone.